The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer

Gynecologic Oncology

Volumn 135, Issue 2, 2014, Pages 349-358

  Secord, Angeles Alvarez ^a   Nixon, Andrew B ^a   Hurwitz, Herbert I ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antiangiogenic agents; Biomarkers; Epithelial ovarian cancer

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN 1; ANGIOPOIETIN 2; BEVACIZUMAB; BIOLOGICAL MARKER; CD31 ANTIGEN; CISPLATIN; DOCETAXEL; FIBROBLAST GROWTH FACTOR; FLUOROURACIL; GEMCITABINE; INTERLEUKIN 6; MESOTHELIN; MOTESANIB; OCTREOTIDE; OROSOMUCOID; OSTEOPONTIN; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; STROMAL CELL DERIVED FACTOR 1; TEMSIROLIMUS; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN D; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; TUMOR MARKER;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CAPILLARY DENSITY; CIRCULATING TUMOR CELL; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC TEST ACCURACY STUDY; DRUG EFFICACY; DRUG SAFETY; EPIGENETICS; EVENT FREE SURVIVAL; GENE EXPRESSION PROFILING; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MALIGNANT ASCITES; MICROARRAY ANALYSIS; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVARY CANCER; OVARY CARCINOMA; PERFUSION WEIGHTED IMAGING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; DISEASE FREE SURVIVAL; FEMALE; METABOLISM; NEOPLASM; NEOVASCULARIZATION, PATHOLOGIC; OVARY TUMOR; PROGNOSIS; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84913610076     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.08.033     Document Type: Review

References (93)

1. R.A. Burger Overview of anti-angiogenic agents in development for ovarian cancer Gynecol Oncol 121 2011 230 238
2. W.A. Spannuth, A.K. Sood, and R.L. Coleman Angiogenesis as a strategic target for ovarian cancer therapy Nat Clin Pract Oncol 5 2008 194 204
3. N.R. Smith, D. Baker, and N.H. James Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers Clin Cancer Res 16 2010 3548 3561
4. R.A. Burger, M.F. Brady, and M.A. Bookman Incorporation of bevacizumab in the primary treatment of ovarian cancer N Engl J Med 365 2011 2473 2483
5. T.J. Perren, A.M. Swart, and J. Pfisterer A phase 3 trial of bevacizumab in ovarian cancer N Engl J Med 365 2011 2484 2496
6. C. Aghajanian, S.V. Blank, and B.A. Goff OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer J Clin Oncol 30 2012 2039 2045
7. E. Pujade-Lauraine, F. Hilpert, and B. Weber AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC) J Clin Oncol 30 2012 [Abstract LBA5002]
8. B.A. Goff Advanced ovarian cancer: what should be the standard of care? J Gynecol Oncol 24 2013 83 91
9. A. du Bois, G. Kristensen, and I. Ray-Coquard AGO-OVAR 12: a randomized placebo-controlled GCIG/ENGOT-intergroup phase III trial of standard frontline chemotherapy +/- nintedanib for advanced ovarian cancer Int J Gynecol Cancer 23 2013 LBA 1
10. J.A. Ledermann, T.J. Perren, and F.A. Raja Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: results of the ICON6 trial Presented at: the European Cancer Congress; September 27-October 1, 2013; Amsterdam, Netherlands 2013 [Abstract 10]
11. B.J. Monk, A. Poveda, and I. Vergote A phase III, randomized, double-blind trial of weekly paclitaxel plus the angiopoietin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer: TRINOVA-1 Presented at: the European Cancer Congress; September 27-October 1, 2013; Amsterdam, Netherlands 2013 [Abstract 41]
12. M. Toi, T. Matsumoto, and H. Bando Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications Lancet Oncol 2 2001 667 673
13. B.C. Cooper, J.M. Ritchie, and C.L. Broghammer Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer Clin Cancer Res 8 2002 3193 3197
14. S.K. Kassim, E.M. El-Salahy, and S.T. Fayed Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients Clin Biochem 37 2004 363 369
15. L. Li, L. Wang, and W. Zhang Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer Anticancer Res 24 2004 1973 1979
16. L.A. Hefler, R. Zeillinger, and C. Grimm Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer Gynecol Oncol 103 2006 512 517
17. T.J. Duncan, A. Al-Attar, and P. Rolland Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies? Clin Cancer Res 14 2008 3030 3035
18. E.S. Han, R.A. Burger, and K.M. Darcy Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer Gynecol Oncol 119 2010 484 490
19. P.S. Hegde, A.M. Jubb, and D. Chen Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab Clin Cancer Res 19 2013 929 937
20. D. Lambrechts, H.J. Lenz, S. de Haas, P Carmeliet, and S.J. Scherer Markers of response for the antiangiogenic agent bevacizumab J Clin Oncol 31 2013 1219 1230
21. J. Schmitt, and D. Matei Targeting angiogenesis in ovarian cancer Cancer Treat Rev 38 2012 272 283
22. Y. Doi, M. Yashiro, and N. Yamada Significance of phospho-vascular endothelial growth factor receptor-2 expression in pancreatic cancer Cancer Sci 101 2010 1529 1535
23. I. Johansson, K.E. Aaltonen, and A. Ebbesson Increased gene copy number of KIT and VEGFR2 at 4q12 in primary breast cancer is related to an aggressive phenotype and impaired prognosis Genes Chromosomes Cancer 51 2012 375 383
24. M.J. Birrer, H. Lankes, and R.A. Burger Biomarker (BM) results from GOG-0218, a phase 3 trial of front-line bevacizumab (BV) + chemotherapy (CT) for ovarian cancer (OC) Ann Oncol 23 ix81 2012 [Abstract 198P]
25. A.K. Olsson, A. Dimberg, J. Kreuger, and L. Claesson-Welsh VEGF receptor signalling - in control of vascular function Nat Rev Mol Cell Biol 7 2006 359 371
26. S.J. Oh, M.M. Jeltsch, and R. Birkenhager VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane Dev Biol 188 1997 96 109
27. B.H. Jeon, C. Jang, and J. Han Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b + macrophages in advanced ovarian cancer Cancer Res 68 2008 1100 1109
28. S.A. Stacker, M.G. Achen, L. Jussila, M.E. Baldwin, and K. Alitalo Lymphangiogenesis and cancer metastasis Nat Rev Cancer 2 2002 575 583
29. A.M. Jubb, K.D. Miller, and H.S. Rugo Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer Clin Cancer Res 17 2011 372 381
30. Y. Yokoyama, D.S. Charnock-Jones, and D. Licence Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma Br J Cancer 88 2003 237 244
31. A.B. Nixon, H. Pang, and M.D. Starr Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance) Clin Cancer Res 19 2013 6957-6966
32. F. Collinson, M. Hutchinson, and R.A. Craven Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection Clin Cancer Res 19 2013 5227 5239
33. W.A. Spannuth, A.M. Nick, and N.B. Jennings Functional significance of VEGFR-2 on ovarian cancer cells Int J Cancer 124 2009 1045 1053
34. F.Q. Wang, E. Barfield, S. Dutta, T. Pua, and D.A. Fishman VEGFR-2 silencing by small interference RNA (siRNA) suppresses LPA-induced epithelial ovarian cancer (EOC) invasion Gynecol Oncol 115 2009 414 423
35. Y. Crawford, I. Kasman, and L. Yu PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment Cancer Cell 15 2009 21 34
36. C. Lu, A.A. Kamat, and Y.G. Lin Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma Clin Cancer Res 13 2007 4209 4217
37. C. Lu, P.H. Thaker, and Y.G. Lin Impact of vessel maturation on antiangiogenic therapy in ovarian cancer Am J Obstet Gynecol 198 2008 477 479
38. G.C. Jayson, G.J. Parker, and S. Mullamitha Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab′, leads to fluid accumulation and is associated with increased tumor vascularized volume J Clin Oncol 23 2005 973 981
39. M.J. Birrer, M.E. Johnson, and K. Hao Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas J Clin Oncol 25 2007 2281 2287
40. I.A. Steele, R.J. Edmondson, J.N. Bulmer, B.S. Bolger, H.Y. Leung, and B.R. Davies Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer Oncogene 20 2001 5878 5887
41. J. Yoneda, H. Kuniyasu, M.A. Crispens, J.E. Price, C.D. Bucana, and I.J. Fidler Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice J Natl Cancer Inst 90 1998 447 454
42. A. Sako, J. Kitayama, and H. Yamaguchi Vascular endothelial growth factor synthesis by human omental mesothelial cells is augmented by fibroblast growth factor-2: possible role of mesothelial cell on the development of peritoneal metastasis J Surg Res 115 2003 113 120
43. D.P. Barton, A. Cai, K. Wendt, M. Young, A. Gamero, and S. De Cesare Angiogenic protein expression in advanced epithelial ovarian cancer Clin Cancer Res 3 1997 1579 1586
44. O. Casanovas, D.J. Hicklin, G. Bergers, and D. Hanahan Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors Cancer Cell 8 2005 299 309
45. T.T. Batchelor, A.G. Sorensen, and E. di Tomaso AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients Cancer Cell 11 2007 83 95
46. F. Bach, F.J. Uddin, and D. Burke Angiopoietins in malignancy Eur J Surg Oncol 33 2007 7 15
47. S.F. Winter, V.D. Acevedo, R.D. Gangula, K.W. Freeman, D.M. Spencer, and N.M. Greenberg Conditional activation of FGFR1 in the prostate epithelium induces angiogenesis with concomitant differential regulation of Ang-1 and Ang-2 Oncogene 26 2007 4897 4907
48. A. Peled, O. Wald, and J. Burger Development of novel CXCR4-based therapeutics Expert Opin Investig Drugs 21 2012 341 353
49. F. de Nigris, C. Schiano, T. Infante, and C. Napoli CXCR4 inhibitors: tumor vasculature and therapeutic challenges Recent Pat Anticancer Drug Discov 7 2012 251 264
50. A. Aguilar-Mahecha, M. Basik, and J.W. Chapman Measurement of baseline serum SDF-1 levels as a predictive biomarker for outcomes in the NCIC CTG MA. 14 trial of octreotide, a somatostatin analogue in postmenopausal breast cancer J Clin Oncol 29 2011 [Abstract 577]
51. H. Kim, M.Y. Lee, and T.S. Ahn Angiogenic marker associated with resistance to neoadjuvant chemoradiotherapy in rectal cancer J Clin Oncol 31 2013 [Abstract 11030]
52. N.I. Johnston, V.K. Gunasekharan, A. Ravindranath, C. O'Connell, P.G. Johnston, and M.K. El-Tanani Osteopontin as a target for cancer therapy Front Biosci 13 2008 4361 4372
53. M. Nakae, I. Iwamoto, and T. Fujino Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer J Obstet Gynaecol Res 32 2006 309 314
54. O. Yazici, H. Akbulut, N. Akgun, G. Utkan, B. Yalcin, and F. Idi The role of serum osteopontin (OPN) as a prognostic and predictive marker in patients with advanced gastric cancer J Clin Oncol 29 2011 [Abstract e14627]
55. E.M. Dijkgraaf, M.J. Welters, J.W. Nortier, S.H. van der Burg, and J.R. Kroep Interleukin-6/interleukin-6 receptor pathway as a new therapy target in epithelial ovarian cancer Curr Pharm Des 18 2012 3816 3827
56. H.T. Tran, Y. Liu, and A.J. Zurita Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials Lancet Oncol 13 2012 827 837
57. A.B. Nixon, S. Halabi, and I. Shterev Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): results from CALGB 90206 (Alliance) J Clin Oncol 31 2013 [Abstract 4520]
58. J. Heymach, H.T. Tran, and A.B. Nixon Circulating cytokines and angiogenic factors (CAF) as markers of clinical response in the study of trametinib (T) plus gemcitabine (G) versus placebo (P) plus gemcitabine for patients (pts) with untreated metastatic adenocarcinoma of the pancreas (MEK113487) J Clin Oncol 31 2013 [Abstract 4042]
59. J.S. de Bono, H.I. Scher, and R.B. Montgomery Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer Clin Cancer Res 14 2008 6302 6309
60. C.M. Rudin, A. Mauer, and M. Smakal Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer J Clin Oncol 29 2011 1075 1082
61. M. Cristofanilli, G.T. Budd, and M.J. Ellis Circulating tumor cells, disease progression, and survival in metastatic breast cancer N Engl J Med 351 2004 781 791
62. K. Behbakht, M.W. Sill, and K.M. Darcy Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study Gynecol Oncol 123 2011 19 26
63. R.J. Schilder, M.W. Sill, and H.A. Lankes A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study Gynecol Oncol 129 2013 86 91
64. D. Wang, C.R. Stockard, and L. Harkins Immunohistochemistry in the evaluation of neovascularization in tumor xenografts Biotech Histochem 83 2008 179 189
65. A.H. Beck, N.W. Knoblauch, and M.M. Hefti Significance analysis of prognostic signatures PLoS Comput Biol 9 2013 e1002875
66. S. Bentink, B. Haibe-Kains, and T. Risch Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer PLoS One 7 2012 e30269
67. S. Siamakpour-Reihani, K. Owzar, and C. Jiang Prognostic significance of differential expression of angiogenic genes in women with invasive high-grade serous ovarian carcinoma J Clin Oncol 31 2013 [Abstract 5509]
68. G.E. Konecny, C. Wang, and B. Winterhoff Prognostic relevance of gene signatures in high-grade serous ovarian carcinoma J Clin Oncol 31 2013 [Abstract 5510]
69. R. Ben-Hamo, and S. Efroni Biomarker robustness reveals the PDGF network as driving disease outcome in ovarian cancer patients in multiple studies BMC Syst Biol 6 2012 3
70. J.K. Chan, T.K. Kiet, and K. Blansit MiR-378 as a biomarker for response to anti-angiogenic treatment in ovarian cancer Gynecol Oncol 133 2014 568 574
71. C.J. Chang, and M.C. Hung The role of EZH2 in tumour progression Br J Cancer 106 2012 243 247
72. C. Lu, H.D. Han, and L.S. Mangala Regulation of tumor angiogenesis by EZH2 Cancer Cell 18 2010 185 197
73. B.P. Schneider, M. Wang, and M. Radovich Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100 J Clin Oncol 26 2008 4672 4678
74. C. Gourley, A. McCavigan, and T. Perren Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab J Clin Oncol 32 2014 [Abstract 5502]
75. B.J.N. Winterhoff, S. Kommoss, and A.L. Oberg Bevacizumab and improvement of progression-free survival (PFS) for patients with the mesenchymal molecular subtype of ovarian cancer Presented at the 50th American Society of Clinical Oncology (ASCO) Annual Meeting; May 30-June 3, 2014; Chicago, IL 2014
76. J.S. Ferriss, J. Java, and R.A. Burger Predictors of outcomes in gynecologic cancers: what can we learn? Ascites predicts degree of treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube, and peritoneal cancers http://www.mdlinx.com/cardiology/conference-abstract.cfm/3661/
77. R. Dienstmann, I. Brana, J. Rodon, and J. Tabernero Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs Oncologist 16 2011 1729 1740
78. S.M. Wilhelm, C. Carter, and L. Tang BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 2004 7099 7109
79. S. Goel, D.G. Duda, and L. Xu Normalization of the vasculature for treatment of cancer and other diseases Physiol Rev 91 2011 1071 1121
80. J.P. O'Connor, C.J. Rose, and A. Jackson DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6 Br J Cancer 105 2011 139 145
81. P. Vaupel, and A. Mayer Hypoxia in cancer: significance and impact on clinical outcome Cancer Metastasis Rev 26 2007 225 239
82. K.A. Krohn, J.M. Link, and R.P. Mason Molecular imaging of hypoxia J Nucl Med 49 Suppl. 2 2008 129S 148S
83. X. Zhang, T. Melo, J.R. Ballinger, and A.M. Rauth Studies of 99mTc-BnAO (HL-91): a non-nitroaromatic compound for hypoxic cell detection Int J Radiat Oncol Biol Phys 42 1998 737 740
84. D.J. Honess, S.A. Hill, and D.R. Collingridge Preclinical evaluation of the novel hypoxic marker 99mTc-HL91 (Prognox) in murine and xenograft systems in vivo Int J Radiat Oncol Biol Phys 42 1998 731 735
85. S.T. Lee, and A.M. Scott Hypoxia positron emission tomography imaging with 18f-fluoromisonidazole Semin Nucl Med 37 2007 451 461
86. E.S. Han, M. Wakabayashi, and L. Leong Angiogenesis inhibitors in the treatment of epithelial ovarian cancer Curr Treat Options Oncol 14 2013 22 33
87. F. Hilberg, G.J. Roth, and M. Krssak BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy Cancer Res 68 2008 4774 4782
88. S.R. Brave, K. Ratcliffe, and Z. Wilson Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family Mol Cancer Ther 10 2011 861 873
89. A. du Bois, A. Floquet, and J. Weon Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16) J Clin Oncol 31 2013 [Abstract LBA 5503]
90. F. Heitz, R.C. Gagnon, and S.Y. Park Genomic alterations in paired pretreatment (pre) and progression (prog) tumor samples from ovarian cancer patients (pts) treated with pazopanib (pazo) or placebo (plb) Presented at the 50th American Society of Clinical Oncology (ASCO) Annual Meeting; May 30-June 3, 2014; Chicago, IL 2014
91. B.Y. Karlan, A.M. Oza, and G.E. Richardson Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer J Clin Oncol 30 2012 362 371
92. B.J. Monk, A. Poveda, and I. Vergote Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial Lancet Oncol 15 2014 799 808
93. R.J. Buckanovich, R. Berger, and A. Sella Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): results from a phase II randomized discontinuation trial (RDT) J Clin Oncol 29 2011 [Abstract 5008]